A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date22/10/24 → 21/10/29